Printer Friendly Version  View printer-friendly version
<< Back
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2005

BOULDER, Colo., May 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Array BioPharma Inc. (Nasdaq: ARRY) today reported financial results for the third quarter of fiscal 2005, ended March 31, 2005.

For the third quarter of fiscal 2005, Array reported total revenue of $11.6 million, compared to revenue of $9.7 million for the same period in fiscal 2004. Collaboration revenue increased $1.3 million, compared to the same period last year, from new and expanded research collaborations. Net loss was $6.2 million, or ($0.16) per share, for the third quarter, compared to a net loss of $9.7 million, or ($0.34) per share, for the same quarter in fiscal 2004. Array ended the third quarter of fiscal 2005 with $90.5 million in cash and marketable securities.

"We are advancing our product pipeline, focused primarily on treatments for cancer and inflammatory disease, and we are on track to file two INDs in 2005," said Robert E. Conway, Chief Executive Officer, Array BioPharma. "In addition, we are delighted to have expanded our collaboration with Genentech, further validating our leadership position in small molecule cancer research."

Recent Accomplishments:

Advancing Proprietary Research Programs

  • Continued progress on the Phase I clinical trial for ARRY-142886 (AZD6244), a novel MEK inhibitor for cancer discovered by Array and out-licensed to AstraZeneca.
  • Advanced regulated preclinical safety testing and formulation studies for ARRY-334543, a potent, orally active, small molecule inhibitor of EGFR and ErbB-2 (dual inhibitor) for use in the treatment of cancer. Presented preclinical data on this compound at the recent American Association for Cancer Research conference.
  • Evaluated select compounds in advanced efficacy and tolerability models from the p38 and MEK inhibitor target classes for inflammation and from the ErbB-2 inhibitor target class for cancer.
  • Continued research on several other proprietary programs that are in early preclinical evaluation, lead optimization and lead generation.

Expanding Research Collaborations
  • Expanded a collaboration agreement with Genentech, Inc. to develop small molecule drugs against an additional protein target in the field of oncology. The original collaboration, which began in January 2004, was formed to advance two of Array's proprietary oncology programs into clinical development. Under the expanded agreement, Array will receive additional research funding, as well as research and development milestone payments and product royalties based on the success of the new program. Genentech will have the sole responsibility for clinical development and commercialization of the resulting products.

Array reported revenue of $33.5 million for the nine-month period ended March 31, 2005, compared to revenue of $24.5 million for the same period in fiscal 2004. Net loss for the nine months ended March 31, 2005, was $16.7 million, or ($0.51) per share, compared to a net loss of $21.9 million, or ($0.77) per share, reported in the same period in fiscal 2004.

Array will hold a conference call on Tuesday, May 10, 2005, at 9:00 a.m. eastern time to discuss these results. If there is any additional information provided during this call, it will be available on a replay of the call and as a web cast on Robert E. Conway, Chief Executive Officer, and Michael Carruthers, Chief Financial Officer, will lead the call.

Conference Call Information
Date: Tuesday, May 10, 2005
Time: 9:00 a.m. eastern time
Toll-Free: (800) 478-6251
Toll: (913) 981-5558
Pass Code: 4484757
Web Cast:

There will be a replay of the conference call for one week, which can be accessed in the United States by dialing toll-free (888) 203-1112, and outside the United States (719) 457-0820. The access code is 4484757. Replay of the call will also be available as a web cast on Array's web site at

About Array BioPharma:

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to address significant unmet medical needs. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. In addition, leading pharmaceutical and biotechnology companies access our drug discovery technologies and expertise through collaborations to design, create, optimize and evaluate drug candidates across a broad range of therapeutic areas. For more information on Array, please go to

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2004, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties for their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet drug objectives, including clinical trials, tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of May 9, 2005. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

Array BioPharma Inc.
                      Condensed Statement of Operations
                   (in thousands, except per share amounts)

                                     Three Months Ended   Nine Months Ended
                                         March 31,             March 31,
                                      2005       2004      2005        2004
                                        (unaudited)          (unaudited)
      Collaboration revenue          $8,919     $7,667    $25,812    $21,585
      License and milestone revenue   2,637      2,021      7,649      2,893
       Total revenue                 11,556      9,688     33,461     24,478

     Operating expenses:
      Cost of revenue including
       related research and
       development                    9,573      8,480     27,830     22,962
      Provision for excess
       inventory                         --      5,616         --      5,616
      Research and development for
       proprietary drug discovery     6,476      3,511     16,270     12,108
      Selling, general and
       administrative                 2,316      1,912      6,992      5,990
       Total operating expenses      18,365     19,519     51,092     46,676

     Loss from operations            (6,809)    (9,831)   (17,631)   (22,198)
     Interest income                    574         99        904        268
     Net loss                       $(6,235)   $(9,732)  $(16,727)  $(21,930)

     Basic and diluted net loss
      per share                      $(0.16)    $(0.34)    $(0.51)    $(0.77)

     Number of shares used to
      compute per share data         38,309     28,601     32,599     28,416

                          Summary Balance Sheet Data
                                (in thousands)

                                                  March 31,         June 30,
                                                    2005              2004
     Cash, cash equivalents and marketable
      securities                                  $90,503           $37,446
     Property, plant and equipment, gross          61,764            57,557
     Working capital                               75,493            25,905
     Total assets                                 127,708            77,764
     Stockholders' equity                         106,610            55,630

SOURCE Array BioPharma Inc.

Tricia Haugeto of Array BioPharma Inc.,

ShareThis Copy and Paste